Every letter we have printed

Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?

As an anaesthetist I read the perioperative section with interest and one objection. You frame disclosure as the patient obligation. In my experience the failure is more often ours: the pre-assessment questionnaire in my own institution did not include these drugs until eighteen months after the first guidance appeared.

The gallbladder section says some of the excess is attributable to weight loss rather than the drug. If the drug causes the weight loss, is that not a distinction without a difference for the person who ends up in theatre?

You report the STEP 1 nausea figure as approximately forty-four per cent. The publication gives 44.2 per cent. Given how much of your argument rests on precision about what these numbers mean, the rounding sits oddly.

A small thing but it matters in practice: your table gives amylase and lipase rising as a finding of unclear significance. In my laboratory we no longer report amylase at all for suspected pancreatitis, because lipase is more sensitive and more specific and having both invites the wrong one to be acted on.

My ferritin fell from 118 to 34 across a year on treatment and I was told this was expected because inflammation had fallen. Six months later I was clearly iron deficient. I appreciate the section on this being ambiguous, but the ambiguity was resolved in one direction and nobody looked.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.

You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?

I have worked in aseptic fill for nineteen years and your section on media fills understates one thing. The scale is not the hard part. Running the simulation with every intervention the real process contains — every stopper jam, every environmental sample, every gowning break — is the hard part, and a simulation that omits the interventions is theatre with a growth medium in it.

I had a nine-week gap last year because my supplier stopped answering messages. Nobody in any clinical setting I dealt with treated that as a pharmacological event. Your framing of supply interruption as a dosing decision is the first time I have seen it written down.

A small thing. You give the semaglutide diabetes ladder as ending at 2.0 mg and the weight ladder at 2.4 mg, without explaining why the same molecule has two ceilings for two indications. It looks arbitrary and I suspect it is not.

The claim that nobody has randomised escalation intervals is too strong. There are protocol amendments in several programmes that effectively created slower-titration cohorts, and some of those have been analysed post hoc.

You describe the plateau as an energy-balance event and dismiss receptor desensitisation. Is there not a third possibility — that adherence quietly falls off at around a year and the plateau is partly a behavioural artefact of the trial rather than a physiological one?

As a prescribing pharmacist I would add one thing about re-titration. The commonest problem I see is not the resumption dose. It is that the patient has a pen left over at the old strength and uses it because it is in the fridge and it cost money. The clinical decision and the economic decision are not the same decision.

As an anaesthetist I read the perioperative section with interest and one objection. You frame disclosure as the patient obligation. In my experience the failure is more often ours: the pre-assessment questionnaire in my own institution did not include these drugs until eighteen months after the first guidance appeared.

The gallbladder section says some of the excess is attributable to weight loss rather than the drug. If the drug causes the weight loss, is that not a distinction without a difference for the person who ends up in theatre?

Your figures show diarrhoea at thirty-two per cent and constipation at twenty-three per cent in the same trial arm. I assumed one of these was an error until your mechanism section. It would be worth putting that explanation before the table rather than after it.

I want to push back on the ginger paragraph. You describe the evidence as transferred from pregnancy and chemotherapy, which is accurate, and then include it in the table anyway. Either it belongs or it does not.

Your residual-exposure table gives six per cent after four weeks. I calculate 6.25 per cent, which is a quibble, but the larger point is that it assumes steady state at the moment of interruption. Someone who stops three weeks into a new rung has less on board than your table implies.

I take this for kidney disease, not for weight. Every piece of writing I encounter about stopping is about the weight coming back. It has taken me a year to find anybody willing to say plainly that the renal benefit accrued over years of treatment and nobody has tested what happens if I stop.

Nothing in this file addresses what to do when you realise mid-week that you have made an error. I gave double my dose on a Sunday and could find no guidance anywhere about what that meant.

I gave myself a tenth of my intended dose for five weeks. I had been using insulin syringes, ran out, and used the 1 mL syringes that came with the vials, which are marked in millilitres. I did not notice because the plunger was in roughly the same place. Nobody warned me these were different scales.

Your needle-length section says four millimetres is adequate for all adults, which contradicts what I was told by a nurse who insisted on half an inch because of my weight. Which is right?

You recommend writing the concentration on the vial. I would add: write it on the box as well. My vial label came off in the fridge and I lost the only record of what diluent volume I had used.

Your rotation advice says site does not affect absorption in this class, and then says to rotate anyway. If absorption is unaffected, why bother?

On the section about diode-array detection and peak purity, I would add that true peak purity assessment requires library matching or at least spectral comparison across the peak width. A homogeneous spectrum tells you the peak is probably pure. A spectrum that shifts across the peak tells you it is not, and that information closes a gap the article identifies correctly.

You write that only one laboratory attached its chromatogram to the private buyer report. That was probably us. We started doing it five years ago because the PDF seemed incomplete without it. It costs us nothing to add — the instrument generates it automatically — and it solves exactly the dispute-resolution problem you describe. More laboratories should do it, and the reason they do not is not technical.

Something your article omits, and it changes where the responsibility sits. Method selection is frequently specified by the customer, not by us. A purchase order arrives asking for a peptide purity run at a stated price and turnaround, and the method that fits those two constraints is the method that runs. We are perfectly willing to develop a longer separation for anybody who wants one, and in eleven years almost nobody has asked.

Your worked example varies gradient and threshold together and reports a 1.8-point spread. Which of the two contributed more? The article does not say, and the answer matters for what you are asking suppliers to disclose first.

A small thing but it matters in practice: your table gives amylase and lipase rising as a finding of unclear significance. In my laboratory we no longer report amylase at all for suspected pancreatitis, because lipase is more sensitive and more specific and having both invites the wrong one to be acted on.

My ferritin fell from 118 to 34 across a year on treatment and I was told this was expected because inflammation had fallen. Six months later I was clearly iron deficient. I appreciate the section on this being ambiguous, but the ambiguity was resolved in one direction and nobody looked.

I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.

On amber glass: it is not merely cheap, it is standard in the wider chemical supply trade for anything with a chromophore. The fact that this market ships peptides in clear glass is a sign of who is doing the filling more than of any decision about photostability.

Parcel 7 reached thirty-eight degrees for nearly four hours and you then tell readers not to worry unduly. I accept the solid-state argument. I would still like to know what the material looked like on analysis, and your article does not say.

Your table of degradation pathways lists racemisation and then says it is essentially never reported. If it is never reported, on what basis do you list it as a real risk rather than a theoretical one?

You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?

As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.

On multiple-dose closures: the puncture budget you refer to is generally in single figures for a standard lyophilisation stopper, and the qualification uses a new needle each time. Anybody reusing a needle through the same entry point is outside the data entirely.

Why did you submit only two vials for sterility testing when the whole article argues that the sample size is the problem? Two is worse than twenty by exactly the argument you make.